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Abstract
Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within
6 months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease
relapsed during or within 6 months after completion of platinum-based therapy received the novel microtu-
bule-targeting agent patupilone. Patupilone was well tolerated and demonstrated promising efficacy in this
difficult-to-treat population.
Background: Patients with ovarian cancer whose disease relapses or progresses within 6 months after frontline
platinum- and taxane-containing therapy have a poor prognosis and limited treatment options. In this phase II study,
the activity and safety profiles of patupilone, a novel microtubule-targeting agent, were assessed in patients with
platinum-resistant or -refractory ovarian, primary fallopian tube, or primary peritoneal cancer. Patients and Methods:
Patients whose disease relapsed while they were either receiving or within 6 months after completion of their most
recent platinum-based therapy were given patupilone 10 mg/m2 by a 20-minute intravenous infusion once every
3 weeks (q3w). The primary study endpoint was the overall response rate (ORR), defined as the percentage of patients
with a complete or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
Results: Patients (N  112) received a median of 4 cycles of patupilone. Median overall survival was 11.2 months.
The ORR was 6.3%. Disease control according to RECIST was observed in 57 (50.9%) patients (7 [6.3%] PRs, 50
[44.6%] stable disease). Median duration of disease control was 5.4 months, whereas median progression-free
survival was 2.8 months. Diarrhea, the most common adverse event (AE) regardless of relationship to study drug
(55.4% grade 1/2, 25.0% grade 3/4), was predictable and generally manageable. Other AEs, including nausea,
vomiting, fatigue, and peripheral neuropathy, were generally mild. Conclusion: Patupilone was well tolerated and
demonstrated an encouraging disease control rate in these patients with platinum-resistant or -refractory disease;
this is a challenging population with a poor prognosis.
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54 COvarian cancer is the leading cause of gynecologic-related cancer
deaths in the United States.1 The vast majority (75%) of patients
resent with advanced disease, which has a 5-year survival rate of only
5% to 30%. First-line treatment for advanced disease is platinum-
nd taxane-based chemotherapy.2 Unfortunately, more than 50% of
these patients will have a relapse that is considered incurable. Those
whose disease relapses either during or within 6 months after plati-
num and taxane therapy have a poor prognosis.
Patupilone, a novel microtubule-targeting agent, is effective
against both wild-type and common mutant forms of its molecular
target, -tubulin. It is also a poor substrate for the P-glycoprotein
fflux pump, thereby overcoming key mechanisms of taxane insen-
itivity and resistance. Further, it is water soluble, has a long terminal
alf-life in the blood circulation, and shows high retention in exper-
mental solid tumors.3-7 The clinical benefit of these features has
een demonstrated in solid tumors that are insensitive, resistant, and
efractory to taxanes.7-11
In a phase I dose-escalation study (6.5-11.0 mg/m2 every 3 weeks
q3w]; N  45), patupilone demonstrated efficacy and had a man-
geable safety profile in patients with relapsed or recurrent ovarian
ancer after taxane and platinum therapy.12 Responses were seen at
doses as low as 7.0 mg/m2, and the overall response rate (ORR) was
9.4%. Stable disease (SD) was achieved in another 30.6% of pa-
ients. In the study, the maximum tolerated dose was not reached
ased on dose-limiting toxicities in the first cycle. The 10 mg/m2
dose was recommended for additional studies based on adverse
events (AEs) in subsequent cycles.
Here we present a phase II open-label study of the efficacy, safety,
and pharmacokinetics (PK) of patupilone monotherapy (10 mg/m2
q3w) in patients with platinum-resistant or -refractory ovarian, pri-
mary fallopian tube, or primary peritoneal cancer.
Materials and Methods
Patient Eligibility
Women 18 years of age or older with a World Health Organiza-
tion performance status of 0 to 2 and histologically or cytologically
documented ovarian, primary fallopian tube, or primary peritoneal
cancer who had received up to 3 previous chemotherapy regimens
were eligible for the study. Patients must have received a taxane/
platinum-based combination as the first-line regimen, with carbo-
platin greater than or equal to the area under the concentration-time
curve (AUC) 5 or cisplatin greater than or equal to 75 mg/m2 intra-
enously or 100 mg/m2 intraperitoneally. Patients must have had
progressive disease (PD) while receiving or within 6 months after
completing at least 4 cycles of this first-line regimen. For patients
who had received 2 or 3 previous regimens, the most recent regimen
must have contained a platinum derivative, and progression must
have occurred while the patient was receiving or within 6 months
after completing the last regimen. Patients receiving consolidation
therapy were permitted to enroll if they experienced documented
disease progression within 6 months after the last platinum-contain-
ing therapy. Patients with measurable disease (as defined by Re-
sponse Evaluation Criteria in Solid Tumors [RECIST]) were eligi-
ble, as were those with nonmeasurable disease. For this study,
patients with nonmeasurable disease were defined as those who had
elevated cancer antigen 125 (CA-125) levels on at least 2 baseline
linical Ovarian & Other Gynecologic Cancer December 2012measurements (1 within 7 days of the start of treatment and the other
not more than 3 months before the start of treatment) and at least 1
of the following: nontarget lesions only (defined as lesions that were
unidimensionally measurable with poorly defined margins), with
both diameters less than or equal to 1 cm or diameters smaller than
the distance between cuts, or the lesions were palpable, with either
diameter less than 2 cm; malignant ascites; peritoneal carcinomato-
sis; or pleural effusion. Patients with an elevated CA-125 level as their
only evidence of disease were not eligible for study enrollment; other
exclusion criteria included peripheral neuropathy (PN) greater than
Common Toxicity Criteria grade 1, unresolved bowel obstruction,
and unresolved diarrhea of any grade within 7 days from the start of
treatment.
The study adhered to the Declaration of Helsinki and Good Clin-
ical Practice guidelines. Approval was obtained from each indepen-
dent ethics committee and local institutional review board. All pa-
tients provided written informed consent.
Study Design
This open-label single-arm phase II multicenter study (http://
Clinicaltrials.gov: NCT00035100) was designed to assess the effi-
cacy and safety of patupilone. The primary study endpoint was
ORR, defined as the percentage of patients with a best overall re-
sponse of complete response (CR) or partial response (PR) according
to RECIST. Secondary endpoints included the disease control rate,
defined as the percentage of patients with a best overall response of
CR, PR, or SD according to RECIST; the CA-125 response rate as
defined by Rustin13; safety and tolerability; overall survival; PK; pro-
ression-free survival (PFS); and duration of response.13
All enrolled patients received patupilone 10 mg/m2 as a 20-minute
ntravenous infusion once q3w until disease progression or unaccept-
ble toxicity occurred. Patients were provided with loperamide for
roactive management of diarrheal symptoms according to protocol
reatment guidelines. A dose-adjustment schedule was outlined in
he protocol for patients experiencing unacceptable toxicity directly
ttributable to patupilone. The protocol called for a temporary ces-
ation of treatment until recovery from toxicity, with continuation at
he most recent dose or a 25% or 50% reduced dose, depending on
oxicity grade and duration. Patients were to be removed from the
tudy if toxicity or study drug interruption persisted longer than
weeks beyond the next scheduled dose according to the protocol.
Assessments
Safety assessments consisting of hematologic evaluation, blood
chemistry panels, urine values, AE monitoring, vital signs, and phys-
ical examinations were conducted at screening, on day 1 of each
cycle, and at the end of the study.
Target and nontarget lesions were assessed every 6 weeks by radio-
logic scans (computed tomography or magnetic resonance imaging).
These scans were centrally reviewed by 2 independent radiologists,
with a third acting as the adjudicator in case of disagreements.
PFS was measured from the date of first study treatment to the
date of documented PD or death, whichever occurred first. If PD was
documented beyond 13 weeks from the last tumor assessment, pa-
tients were censored at the date of the last tumor assessment. Patients
without documented disease progression or death were censored at
the time of the last tumor assessment before any new cancer therapy
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Willem M. Smit et alwas instituted. CA-125 levels were evaluated every 6 weeks by a
central laboratory. In patients with elevated CA-125 levels at base-
line, PR was defined as a 50% or 75% response according to Rustin’s
criteria.13 CA-125 disease progression was defined (also according to
Rustin’s criteria) as greater than or equal to 2 times the upper limit of
normal on 2 occasions for patients who experienced a normalization
of CA-125 levels or as greater than or equal to 2 times the nadir
value on 2 occasions for patients whose CA-125 levels did not
normalize. SD in regard to CA-125 levels was not defined, and if
a patient was not determined to have PR or PD, she was classified
as neither PR nor PD.
Whole blood samples were collected before dosing, at the end of
dose infusion (20 minutes), and at 0.5, 1, 2, 4, 8, 24, 72, 168, 336,
and 504 hours after the start of infusion. Patupilone concentrations
in blood were analyzed by liquid chromatography–tandem mass
spectrometry with a detection limit of 0.1 ng/mL. 13C-labeled patu-
ilone was used as an internal standard.11 PK parameters were deter-
mined using a noncompartmental analysis method (WinNonlin 5.2;
Pharsight, Mountain View, CA), and the AUC was calculated by a
linear trapezoidal method.
Statistical Methods
The ORR was the primary efficacy variable. Several secondary
efficacy endpoints, which included PFS and overall survival, were
also analyzed. Responses were summarized in terms of percentage
rates with 95% exact binomial confidence intervals (CIs). Time-to-
event variables were analyzed using the Kaplan-Meier method.
Kaplan-Meier estimates of the survival function with 95% CIs at
specific time points (using Greenwood’s formula for the standard
error) were computed. All analyses were carried out in SAS 8.2 (SAS
Institute Inc, Cary, NC).
Results
Patients
One hundred twelve patients enrolled in the study, most (92.0%)
presenting with ovarian cancer (Table 1). Although up to 3 previous
regimens were permitted, 79.5% and 20.5% of patients had received
1 and 2 previous chemotherapy regimens, respectively. Most patients
presented with advanced disease at their initial diagnosis (87.5%
stage III/IV), and more than one-half (52.7%) of all patients had PD
during or within 3 months of their last platinum treatment.
Treatment
Patients received a median of 4 cycles of patupilone (range, 1.0-
16.0). The median dose per cycle was close to the planned dose of
10 mg/m2 (Table 2). Dose reductions or delays because of AEs oc-
urred in 32 patients (28.6%). Most patients (76.8% [n  86])
iscontinued treatment because of disease progression. Another
3.4% (n 15) discontinued treatment because of AEs, of which 11
9.8%) were deemed related to the study drug.
Safety
Similar to results of previous studies, diarrhea was the most com-
mon AE (31.3% grade 1, 24.1% grade 2, 22.3% grade 3, and 2.7%
grade 4) (Table 3), which led to dose reductions or delays in
15 patients (13.4%) and discontinuation in 5 patients (4.5%). The
median time to first occurrence of diarrhea (any grade) was 13.5 days d(95% CI, 10-19). Complete resolution of these events (with data
censored 28 days after last study drug dose if a date for return to grade
0 was not available) took a median of 4.0 days (95% CI, 3-6) for any
grade and 8 days (95% CI, 5-13) for grade greater than or equal to 3.
The severity of diarrhea did not increase substantially in later cycles
when compared with the grade reported in the first cycle. For exam-
ple, less than 5% of patients with less than or equal to grade 2
diarrhea in cycle 1 had a grade 3/4 event in cycle 3 or beyond. Nausea
(62.5%), vomiting (48.2%), fatigue (42.9%), and PN (39.3%) were
also common but were mild to moderate in severity. Indeed, PN was
primarily grade 1 (24.1% [n  27]) or grade 2 (10.7% [n  12]),
ith few grade 3 (4.5% [n 5]) and no grade 4 events. Grade 3 PN
esolved to grade 0 in 2 patients after 29 and 52 days, respectively,
nd in a third patient to grade 1 baseline after 43 days. Five patients
Table 1 Patient Demographics and Baseline Disease
Characteristics
Variable N  112
Median age, y (range) 56 (18-85)
Baseline WHO PS, n (%)
0 52 (46.4)
1 49 (43.8)
2 11 (9.8)
Primary Site of Cancer, n (%)
Ovary 103 (92.0)
Peritoneum 7 (6.3)
Fallopian tube 2 (1.8)
Tumor Histologic Type/Cytologic Features, n (%)
Serous 61 (54.5)
Adenocarcinoma 28 (25.0)
Clear cell 5 (4.5)
Endometrioid 4 (3.6)
Mucinous 2 (1.8)
Other 12 (10.7)
Stage at Initial Diagnosis, n (%)
I, II 14 (12.5)
III 77 (68.8)
IV 21 (18.8)
Disease, n (%)
Measurable 97 (86.6)
Nonmeasurable 15 (13.4)
Number of Previous Regimens, n (%)
1 89 (79.5)
2 23 (20.5)
Time from Last Platinum Treatment to Most
Recent Previous Progression, n (%)
 3 mo 59 (52.7)
 3 mo 53 (47.3)
Abbreviations: PS performance status; WHO World Health Organization.iscontinued treatment because of PN. Alopecia was reported in
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56 C12 patients, with only 1 ( 1%) experiencing a grade 2 event. Ob-
erved hematologic toxicities of any grade were minimal (neutrope-
Table 2 Study Drug Exposure and Reason for
Discontinuation
Variable
N  112
Median Mean Range
Duration of Exposure, wk 12.1 14.8 2.3-48.0
Number of Cycles Received 4.0 4.75 1.0-16.0
Average Dose per Cycle, mg/m2 9.98 9.71 5.8-10.8
Reasons for Discontinuation, n (%)
Disease progression 86 (76.8)
Adverse eventa 15 (13.4)
Death 5 (4.5)
Otherb 6 (5.4)
a Includes 1 patient with a nontreatment-related emergent AE.
b Includes consent withdrawal, protocol violations, and study drug no longer required.
Table 3 Adverse Events With Incidence > 10% Regardless
of Study Drug Relationship (N  112)
Event Grade 1/2n (%)
Grade 3/4
n (%)
Gastrointestinal System
Diarrhea 62 (55.4) 28 (25.0)
Nausea 63 (56.2) 7 (6.3)
Vomiting 45 (40.2) 9 (8.0)
Abdominal paina 43 (38.4) 4 (3.6)
Constipation 30 (26.8) 2 (1.8)
Dyspepsia 14 (12.5) —
Nervous System
Peripheral neuropathyb 39 (34.8) 5 (4.5)
Headache 14 (12.5) —
General
Fatigue 39 (34.8) 9 (8.0)
Pyrexia 13 (11.6) 2 (1.8)
Asthenia 10 (8.9) 3 (2.7)
Metabolism and Nutrition
Anorexia 30 (26.8) 7 (6.3)
Dehydration 16 (8.0) 9 (8.0)
Decreased weight 22 (19.6) —
Blood and Lymphatic System
Anemia 22 (19.6) 2 (1.8)
Skin and Subcutaneous
Tissue
Alopecia 12 (10.7) —
a Includes upper abdominal pain.
b Includes peripheral motor neuropathy, peripheral sensory neuropathy, polyneuropathy, hypo-
esthesia, paresthesia, and neuralgia.ia 4%, thrombocytopenia 3%), and no hypersensitivity reac-
linical Ovarian & Other Gynecologic Cancer December 2012tions related to the study drug were reported. Of the 9 deaths that
occurred during treatment or within 28 days of the last dose, none
was deemed related to the study drug. Seven deaths were due to
underlying disease, 1 resulted from sepsis, and another was caused by
pulmonary embolism.
Pharmacokinetics
PK data, collected from 19 of the first 21 patients, showed that the
patupilone blood concentration-time profile declined rapidly after
intravenous infusion (Figure 1). The large volume of distribution
(1140  340 L/m2) was consistent with the extensive tissue distri-
ution of patupilone observed in animal models.6 Similarly, the low
lood clearance (8.9  3.0 L/h/m2), long terminal half-life (111 
8 hours), maximum blood concentration (102  53 ng/mL), and
UC (1266  750 ng/h/mL) were in line with the findings of pre-
ious studies.7,11,12 The relationship between systemic exposure of
patupilone and AEs (eg, severe diarrhea) or efficacy could not be
assessed conclusively because of the small size of the PK analysis set.
Efficacy
Based on the central radiologic review, the best overall response
according to RECIST observed in the total patient population
(N  112) was PR in 7 patients, which equaled an ORR of 6.3%
95% CI, 2.6%-12.5%) (Table 4). An additional 50 patients
44.6%) had SD as their best overall response according to RECIST
Table 4), resulting in a disease control rate (CR  PR  SD) of
0.9% (95% CI, 41.3%-60.5%). Median PFS was 2.8 months (95%
I, 2.0-3.2 months) and median overall survival was 11.2 months
95% CI, 8.3-14.9 months) (Figure 2), with a 1-year overall survival
ate of 48.4%. The median duration of disease control was 5.4
onths (95% CI, 4.2-5.8 months). Similar disease control rates were
bserved in patients for whom the sum of the longest diameter of the
easurable target lesions was less than or equal to 5 cm and greater
han 5 cm at baseline (46.4% and 47.8%, respectively).
In an exploratory analysis, CA-125 response according to Rustin
riteria13 was assessed for the 72 evaluable patients with elevated
Figure 1 Mean Blood Concentration-Time Profiles of
Patupilone in Patients with Ovarian Cancer
(n  19). Error bars represent  standard deviation
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BTable 4 Best Overall Responsea
Variable Measurable Disease (n  97)n (%)
All Patients (N  112)
n (%)
Tumor Size at Baseline < 5 cm(n  28)
> 5 cm
(n  69) —
Complete Response 0 (0) 0 (0) 0 (0)
Partial Response 1 (3.6) 5 (7.2) 7 (6.3)
Stable Disease 12 (42.9) 28 (40.6) 50 (44.6)
Progressive Disease 11 (39.3) 30 (43.5) 43 (38.4)
Unknown 4 (14.3) 6 (8.7) 12 (10.7)
Overall Response, % (95% CI) 3.6 (0.1-18.4) 7.2 (2.4-16.1) 6.3 (2.6-12.5)
Disease Control, % (95% CI) 46.4 (27.5-66.1) 47.8 (35.6-60.2) 50.9 (41.3-60.5)Abbreviation: CI confidence interval.
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58 Cfirmed in 14 patients (19.4%), PD was confirmed in 12 patients
(16.7%), and the remaining 46 patients (63.9%) had neither PR nor
PD in regard to CA-125 levels.
Discussion
Women with ovarian cancer that progresses within 6 months after
a platinum- and taxane-containing regimen have a poor prognosis.
Clinical trials in this patient population demonstrate limited efficacy
of chemotherapy and poor survival outcomes, highlighting the need
for additional treatment options. In this phase II study, patupilone
10 mg/m2 q3w achieved a disease control rate of greater than 50%.
Although it is unclear why the ORR presented here (6.3%) was lower
than that reported in the phase I dose-escalation study (19.5%), the
disease control rate was similar (50.9% vs. 50.0%),12 demonstrating
a signal of activity in this difficult-to-treat, platinum-resistant/refrac-
tory population. These rates are within the range observed for other
single-agent studies in platinum-resistant or -refractory disease.14-20
Upcoming analysis of the recently completed phase III study of patu-
pilone vs. pegylated liposomal doxorubicin will more definitively
characterize the activity of patupilone in this patient population.
The safety profile observed in this study is consistent with results
from other patupilone studies in a wide range of tumor
types.7,9,12,21,22 The most common AE, diarrhea, was predictable
(median time to first occurrence was 13.5 days), generally manage-
able (median dose intensity was close to the planned 10 mg/m2), and
hort in duration (events resolved to grade 0 in a median of 4.0 days).
educing gastrointestinal toxicity through the proactive treatment
nd early management of diarrheal symptoms has been a key goal in
atupilone development. Intriguingly, knowledge of corticosteroid
ontrol of water and electrolyte equilibrium led to a preclinical study
n which prednisone administration reduced chemotherapy-induced
iarrhea without impacting patupilone PK or efficacy.23 These re-
ults are being explored in current clinical studies and suggest that
urther reductions in gastrointestinal AEs are feasible.
Patupilone is a member of the epothilone drug class, a group of
icrotubule-stabilizing agents derived from the myxobacterium
orangium cellulosum. The AE profiles of other epothilones include
eutropenia and neuropathy, which are often dose limiting.24-29 The
icrotubule-stabilizing taxanes, which have demonstrated activity in
latinum-resistant ovarian cancer,16,19 also commonly cause neutro-
enia and neuropathy.30,31 However in the present study, neutrope-
nia was uncommon ( 4%, all grades) and PN was generally mild,
with grade 3 events less than 5% (n  5) and no grade 4 events.
Indeed, 3 of 5 grade 3 PN events resolved within 52 days or less. Thus
the toxicity profile of patupilone is distinct from other microtubule
stabilization agents both in and out of its drug class. Furthermore,
unlike paclitaxel and ixabepilone, patupilone is not formulated with
Cremophor (BASF, Berlin, Germany) or other similar excipients
because of its relatively high water solubility. Therefore the risk of
infusion-related AEs is low, and premedication to manage hypersen-
sitivity is not required.32 Indeed the single hypersensitivity reaction
in this study was reported as not related to study drug administration.
In this platinum-resistant or -refractory ovarian cancer popula-
tion, patupilone at 10 mg/m2 q3w demonstrates promising antitu-
mor activity with a manageable toxicity profile. A phase III random-
ized clinical trial comparing patupilone with pegylated liposomal
linical Ovarian & Other Gynecologic Cancer December 2012doxorubicin in more than 800 patients with platinum-resistant or
-refractory ovarian, primary fallopian tube, or primary peritoneal
cancers has recently been completed. The results of this trial, the
largest ever in this patient population, will further elucidate the role
of patupilone in these patients who have limited treatment options
after relapse or recurrence.
Clinical Practice Points
● Approximately 75% of patients with ovarian cancer present with
advanced disease, which is associated with a 5-year survival rate of
only 25% to 30%.
● Patients whose disease relapses either during or within 6 months
after first-line platinum- and taxane-based chemotherapy have
limited treatment options and a poor prognosis.
● Patupilone is a novel microtubule-targeting agent that is effective
against both wild-type and common mutant forms of -tubulin.
● In a phase I dose-escalation study of patients with relapsed or
recurrent ovarian cancer after taxane and platinum therapy, patu-
pilone was associated with a manageable safety profile, an ORR of
19.4%, and an SD rate of 30.6%.
● In the present multicenter, open-label, single-arm phase II study of
112 patients with platinum-resistant or -refractory ovarian, pri-
mary fallopian tube, or primary peritoneal cancer, patupilone
10 mg/m2 given by 20-minute intravenous infusion once q3w
resulted in an ORR of 6.3%, a disease control rate of 50.9%, a
median PFS of 2.8 months, a median overall survival of
11.2 months, and a 1-year overall survival rate of 48.4%. The
safety profile was consistent with that observed in other patupilone
studies in a wide range of tumor types, with the most common AE,
diarrhea, being predictable, generally manageable, and short in
duration.
● Additional data from a phase III study will further elucidate the
efficacy and safety of patupilone in patients with platinum-resis-
tant or -refractory ovarian cancer.
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